Eignet sich 0,1%ige Timolol-Maleat Augentropflösung zur Therapie des chronischen Glaukoms?

Publisher Website
Google Scholar
Abstract
On the basis of 47 patients with chronic open-angle glaucoma, the administration of 0.1% timolol-maleate eye-drops was investigated in a controlled long-term study over a period of 56 wk. In a remarkable proportion of chronic glaucoma cases, this low concentration had an adequate, long-term effect, reducing IOP [intraocular pressure] by 24-27%. Apparently, in the initial stages of glaucoma, the 0.1% solution is just as effective as solutions of a higher concentration, provided that a satisfactory degree of responsiveness to timolol-maleate is present from the outset. The local and systemic side effects are relatively slight; there are fewer side effects with lower concentrations than with higher concentrations. Since in > 50% of patients with chronic glaucoma, 0.1% timolol-maleate eye-drops reduce IOP adequately over a considerable period of time, the 0.1% solution can be recommended for the initial treatment of glaucoma patients.